Micofenolat Mofetil Sandoz

Mycophenolate Mofetil, the active ingredient in Micofenolat Mofetil Sandoz, is an immunosuppressant presented as an oral tablet for oral use. It is used to prevent organ transplant rejection, treat lupus nephritis, and reduce the risk of graft‑versus‑host disease in transplant recipients. GNH USA supplies Micofenolat Mofetil Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil acts as an antimetabolite immunosuppressant in several transplant‑related and autoimmune conditions. - Organ transplant rejection (kidney, heart, liver): helps prevent acute and chronic rejection by suppressing lymphocyte proliferation. - Lupus nephritis: reduces renal inflammation and proteinuria in patients with systemic lupus erythematosus. - Graft‑versus‑host disease: lowers the incidence and severity of GVHD after hematopoietic stem‑cell transplantation.

Mycophenolate Mofetil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: frequent loose stools. - Headache: transient cranial pain. - Abdominal pain: discomfort in the stomach area. - Upper respiratory infections: increased susceptibility to colds.

Serious or Rare Side Effects: - Leukopenia: significant drop in white blood cells. - Anemia: reduced red blood cell count. - Severe infections: opportunistic or bacterial infections. - Elevated liver enzymes: signs of hepatic stress. - Malignancy risk: potential increased cancer incidence. - Progressive multifocal leukoencephalopathy (PML): rare viral brain infection.

Before initiating therapy, clinicians should assess baseline laboratory values and patient risk factors. - Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Monitor liver function: check transaminases periodically. - Avoid use in pregnancy: drug is contraindicated due to teratogenic risk. - Assess renal function: dose adjustments may be needed in impairment. - Review concomitant nephrotoxic drugs: avoid additive kidney injury. - Store at below 25°C: keep in the original pack, protect from moisture.

Mycophenolate Mofetil interacts with several agents that can alter its safety or efficacy.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Live vaccines: heightened risk of infection. - Cholestyramine: reduces oral absorption of mycophenolic acid.

Moderate Interactions (Monitor Closely): - Cyclosporine or tacrolimus: may increase mycophenolate exposure. - NSAIDs: can exacerbate renal toxicity when combined.